I kliniske fase III studier hos MS- patienter var en samtidig kort kortikosteroid behandling af attakker ikke associeret med en øget hyppighed af infektioner.
In Phase 3 MS clinical trials, concomitant treatment of relapses with a short course of corticosteroids was not associated with an increased rate of infection.